Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 6/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 2/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19796374 | 0.96 | THRB (0.50) | THRBALOX5FFAR1FFAR4HPGD | |
| SCHEMBL19796440 | 0.93 | THRB (0.49) | THRBALOX5FFAR1FFAR4GABRA1 | |
| SCHEMBL19796436 | 0.89 | THRB (0.47) | THRBALOX5FFAR1FFAR4GABRA1 | |
| SCHEMBL19796444 | 0.89 | THRB (0.48) | THRBFFAR1FFAR4 | |
| SCHEMBL19804218 | 0.86 | FFAR4 (0.43) | THRBFFAR1FFAR4PTGER4 | |
| SCHEMBL19796375 | 0.85 | THRB (0.49) | THRBALOX5FFAR1FFAR4HPGD | |
| SCHEMBL19796450 | 0.85 | THRB (0.44) | THRBFFAR1FFAR4 | |
| SCHEMBL19796923 | 0.85 | THRB (0.52) | THRBTHRA | |
| SCHEMBL19804209 | 0.85 | FFAR4 (0.42) | THRBALOX5FFAR1FFAR4PTGER4 | |
| SCHEMBL19796443 | 0.84 | THRB (0.45) | THRBALOX5HPGDTSHRCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | THRB 4323/4885ALOX5 2671/4885FFAR1 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.